Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...

NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...

H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to InvestingPro data, ...

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...

Atara Biotherapeutics will be completing its third large-scale layoff in four years after the biotech company announced that it would be shedding 50% of its workforce by the end of June. Atara, a ...

In a regulatory filing, Atara Biotherapeutics (ATRA) disclosed that on January 27, the company announced a reduction in its workforce that will ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...

Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 40.50%, which has investors questioning if this is right time to ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...